COVID-19 Archives - Page 11 of 16

Developments

Enlivex posts positive COVID-19 results in severe/critical patients

Enlivex Therapeutics (NASDAQ:ENLV) reported positive topline results of an investigator-initiated clinical trial of Allocetra in five COVID-19 patients, three of which were in severe condition and two in critical...

October 1, 2020

Feature

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

aTyr Pharma (NASDAQ:LIFE) expects to report before the end of 2020 results of a Phase 2 study with its ATYR1923 drug candidate in COVID-19-related severe respiratory complications. It also has a data readout planned in...

September 29, 2020

Developments

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 demonstrated positive activity against SARS-CoV-2 in a preclinical study conducted at the National Institute of Allergy and Infectious Diseases (NIAID). Conducted under...

September 17, 2020

Feature

BioCardia developing autologous and allogenic cardiovascular cell therapies

BioCardia (NASDAQ:BCDA) is developing two late-stage clinical autologous cell therapies, known as CardiAMP, for ischemic heart failure and chronic myocardial ischemia, a neurokinin 1 receptor positive (NK1R+) allogenic...

September 15, 2020

Developments

Hepion CRV431 featured on The Bio Report podcast

The Bio Report podcast featured Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 for the treatment of non-alcoholic steatohepatitis (NASH), and potentially, COVID-19. “We’ve kicked off our Phase 2 trial in NASH...

September 11, 2020

Developments

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Vanda Pharmaceuticals (NASDAQ:VNDA) reported interim results from its Phase 3 trial assessing tradipitant for the treatment of COVID-19 pneumonia. The data are based on the first 60 patients enrolled in the study, who...

August 18, 2020

Developments

Omeros reports positive results from COVID-19-associated ARDS trial

Omeros (NASDAQ:OMER) reported positive results from a study evaluating narsoplimab for the treatment of COVID-19-associated acute respiratory distress syndrome (ARDS). Narsoplimab is a human monoclonal antibody that is...

August 10, 2020

Developments

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

The first patients have been enrolled in an investigator-sponsored Phase 2 study evaluating Immunic Therapeutics‘ (NASDAQ:IMUX) IMU-838 for the treatment of COVID-19. IMU-838 is a selective immune modulator that...

July 27, 2020

Developments

Cerecor enrolls first patient in COVID-19 trial

Cerecor (NASDAQ:CERC) enrolled the first patient in its a proof-of-concept trial evaluating CERC-002 in patients with COVID-19 cytokine storm-induced acute respiratory distress syndrome (ARDS). CERC-002 is a...

July 21, 2020

Developments

PhaseBio doses first COVID-19 patient in Phase 2 trial

PhaseBio Pharmaceuticals (NASDAQ:PHAS) dosed the first patient in its potentially pivotal Phase 2 trial evaluating PB1046 for the treatment of high-risk, hospitalized COVID-19 patients. PB1046 is a long-acting analog of...

July 17, 2020

Tag - COVID-19

Enlivex posts positive COVID-19 results in severe/critical patients

aTyr Pharma gearing for data readouts in COVID-19, interstitial lung disease

Hepion CRV431 shows positive activity against SARS-CoV-2 in NIAID study

BioCardia developing autologous and allogenic cardiovascular cell therapies

Hepion CRV431 featured on The Bio Report podcast

Vanda Pharma reports interim results from Phase 3 COVID-19 trial

Omeros reports positive results from COVID-19-associated ARDS trial

Immunic reports first patients enrolled in Phase 2 COVID-19 trial

Cerecor enrolls first patient in COVID-19 trial

PhaseBio doses first COVID-19 patient in Phase 2 trial

General

More